Cardiovascular disease risk and Lung cancer screening for Early Assessment of Risk (project CLEAR) in Missouri: A protocol for a mixed methods study.

Background: Lung cancer and atherosclerotic cardiovascular disease (ASCVD) are leading causes of mortality in the United States, sharing common risk factors like smoking and age. Preventive care for these conditions is often siloed, leading to missed opportunities to prevent ASCVD-related mortality in lung cancer screening (LCS) patients. In various trial settings, patients undergoing LCS were more likely to die from ASCVD than from cancer; however, less than half of eligible patients got statin prescription.

Evaluating a community academic partnership to advance equity-focused cancer genetic implementation research: a qualitative analysis of partner perspectives.

Background: Forming community academic partnerships (CAPs) can increase the applicability, translation, and dissemination of implementation research focused on addressing health inequities within the community setting. We aimed to explore community and academic partners' perspectives on their participation in a novel, multi-disciplinary cancer genetic equity CAP focused on developing a multi-level intervention for breast, ovarian, prostate, and pancreas cancers.

Methods: We conducted semi-structured interviews with CAP members.

Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program.

Involving diverse populations in early-phase (phase I and II) cancer clinical trials is critical to informed therapeutic development. However, given the growing costs and complexities of early-phase trials, trial activation and enrollment barriers may be greatest for these studies at healthcare facilities that provide care to the most diverse patient groups, including those in historically underserved communities (e.g.

Barriers to human papillomavirus (HPV) vaccination among young adults, aged 18-35.

In the United States (US), an estimated 35,900 human papillomavirus (HPV)-related cancers are diagnosed annually. HPV vaccines are projected to eliminate ∼90% of these cancers. Routine vaccination is recommended at age 11-12 with "catch-up" vaccination through age 26 and shared clinical decision making for ages 27-45.

Patients' self-reported barriers to colon cancer screening in federally qualified health center settings.

Colorectal cancer (CRC) is a leading cause of cancer-related death in the United States. Despite evidence that screening reduces CRC incidence and mortality, only about 60% of age-eligible adults are up-to-date on CRC screening. This analysis aims to identify self-reported barriers to CRC screening among patients in a safety-net healthcare setting.

Correlates of human papillomavirus (HPV) vaccination initiation and completion among 18-26 year olds in the United States.

Purpose: To examine correlates of HPV vaccination uptake in a nationally representative sample of 18-26-year-old adults.

Methods: Young adults aged 18-26 years were identified from the 2014 and 2015 National Health Interview Survey (n = 7588). Survey-weighted multivariable logistic regression models estimated sociodemographic factors associated with HPV vaccine initiation (≥1 dose) and completion (≥3 doses).

Conducting a randomized trial in rural and urban safety-net health centers: Added value of community-based participatory research.

Background: Colorectal cancer (CRC) is the second most common cancer in the US. Despite evidence that screening reduces CRC incidence and mortality, screening rates are sub-optimal with disparities by race/ethnicity, income, and geography. Rural-urban differences in CRC screening are understudied even though approximately one-fifth of the US population lives in rural areas.